Advertisement
Advertisement
Julie Zhang
Reporter, Business
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Areas of Expertise:
Corporate finance, IPOSLanguages Spoken:
Cantonese, English, Mandarin
China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth.
Agency says limited exposure to the Middle East has kept trade risks contained for most Hong Kong exporters.
US firm is strengthening its China operations amid an intensifying expansion race with other pharmaceutical giants.
Survey shows family offices expanding risk management while maintaining strong investment exposure to Hong Kong and Asia.
Advertisement
Stock Connect reshuffle reflects biotech sector’s growing role on international stage, though overseas funds remain cautious.
Hong Kong-listed biotech firm’s shares jump after announcing partnership to use AI tools in drug discovery in the United Arab Emirates.
Foreign investors are returning to China’s healthcare sector, but IPO bottlenecks and takeover rules could deter deals, VC Nisa Leung says.
The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.
Healthcare and insurance sectors will see policy fine-tuning, ‘moral support’ rather than ‘groundbreaking news’ from Beijing, analysts say.
Modelled on Stock Connect, the proposal would give investors in the Greater Bay Area cross-border access to new share listings.
Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.
After four subdued years, the cornerstone investors that anchor Hong Kong’s IPO market are returning in force, reshaping the deal landscape.
Slumping profits at Shandong Xinhua Pharmaceutical have dragged the shares to about HK$7 in December 2025 from HK$15.62 in December 2022.
The cost of a single monkey exceeds the average annual salary in China and approaches a pandemic-era spike amid growth in drug licensing deals.
More than 200,000 people file complaints as UBS SDIC’s attempted remedy for sudden change of fund’s price benchmark falls flat with some.
The three companies will be added to the gauge after the market close on March 6, while car dealer Zhongsheng Group will be removed.
The Tsinghua Holdings arm, however, will raise US$800 million via a private share placement on Shenzhen exchange.
A wave of government-linked investment is boosting Chinese AI drug makers, underscoring Beijing’s drive to build its own biotech ecosystem.
Privately owned Distinct Healthcare plans to open a clinic in Dubai, while TCM group Gushengtang eyes 50 centres in Southeast Asia.
An index tracking Stock Connect buying of 40 mainland drug firms gains 9 per cent in a week as China’s industry heft grows.
Three of China’s stock exchanges have relaxed fundraising time thresholds on listed tech companies as Beijing pushes for self-reliance.
Drug makers in China are performing cutting-edge research and licensing products to global giants after a 10-year government push supercharged the industry.
The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners.
Mainland China’s issuers will still dominate city’s IPO market, executive says, but US and Southeast Asian companies are also joining in.
Some retreat to the sidelines as another fund suspends new investments and futures plunge, while others remain determined to buy the dip.
Fifth consecutive sell-out at Sai Sha development shows recovery gathering pace, with analysts forecasting further price increases ahead.
AI and genetics are creating a ‘seismic shift’ in the pharmaceutical business, experts on Asian Financial Forum panel say.
Global institutional investors have built up sizeable positions in firms including Innovent, 3SBio, WuXi Biologics, Jiangsu Hengrui, Akeso and BeOne.
Latest example of Chinese drug maker acquiring equity in overseas partner shows they are becoming true development partners, analysts say.
